Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.76 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.76 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.76 |
| ▸ | HPGD | P15428 | 2/20 | 0.76 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.62 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.57 |
| ▸ | CCR2 | P41597 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | SRD5A2 | P31213 | 2/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GFER | P55789 | 2/20 | 0.43 |
| ▸ | DAO | P14920 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.41 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29897910 | 1.00 | HSD17B10 (0.76) | HSD17B10ALDH1A1KDM4EHPGDMCL1 | |
| SCHEMBL986506 | 0.86 | KDM4E (1.00) | HSD17B10ALDH1A1KDM4EHPGDMCL1 | |
| SCHEMBL3924468 | 0.82 | L3MBTL1 (0.57) | HSD17B10ALDH1A1KDM4EHPGDMCL1 | |
| SCHEMBL30885827 | 0.82 | KDM4E (0.53) | HSD17B10ALDH1A1KDM4EHPGDMCL1 | |
| SCHEMBL29834824 | 0.82 | L3MBTL1 (0.57) | HSD17B10ALDH1A1KDM4EHPGDMCL1 | |
| SCHEMBL10254076 | 0.81 | MCL1 (0.64) | HSD17B10ALDH1A1KDM4EHPGDMCL1 | |
| SCHEMBL8664 | 0.81 | LDHA (0.61) | HSD17B10ALDH1A1KDM4EHPGDMCL1 | |
| SCHEMBL3061835 | 0.81 | MCL1 (0.64) | HSD17B10ALDH1A1KDM4EHPGDMCL1 | |
| SCHEMBL12466580 | 0.80 | CCR2 (0.57) | HSD17B10ALDH1A1KDM4EHPGDMCL1 | |
| SCHEMBL2828847 | 0.79 | MCL1 (0.62) | HSD17B10ALDH1A1KDM4EHPGDMCL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6759428-B2 | SUCH AS N-((1,2)-2-(((CYANO(CYCLOPROPYL)METHYL)AMINO)CARBONYL) CYCLOHEXYL)-1H-INDOLE-2-CARBOXAMIDE; CATHEPSIN K INHIBITORS | ROCHE PALO ALTO LLC | 2004-07-06 | — | — | US | claimed |
| US-20040077646-A1 | Indole nitriles | ROCHE PALO ALTO LLC | 2004-04-22 | — | — | US | claimed |
| CN-114702504-B | Trifluoromethyl substituted indolopyranone compound, preparation method thereof and application thereof in antitumor drugs | 平顶山学院 | 2023-04-07 | — | — | CN | disclosed |
| US-20230039586-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. | 2023-02-09 | — | — | US | disclosed |
| WO-2023287704-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | NIDO BIOSCIENCES, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| CN-114702504-A | Trifluoromethyl substituted indolopyranone compound, preparation method thereof and application thereof in antitumor drugs | 平顶山学院 | 2022-07-05 | — | — | CN | disclosed |
| EP-3831811-A1 | HETEROCYCLIC COMPOUND | Fimecs, Inc. (JP) | 2021-06-09 | — | — | EP | disclosed |
| US-9522140-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2016-12-20 | — | — | US | disclosed |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2015-11-12 | — | — | US | disclosed |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | RAQUALIA PHARMA INC (JP) | 2015-11-12 | — | — | US | disclosed |
| US-9101616-B2 | Aryl substituted carboxamide derivatives as calcium or sodium channel blockers | RAQUALIA PHARMA INC. (JP) | 2015-08-11 | — | — | US | disclosed |
| CN-100406459-C | 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino [4, 5-b ] indole-1-acetamide derivatives, their preparation and use in therapy | SANOFI AVENTIS (FR) | 2008-07-30 | — | — | CN | disclosed |
| CN-100376579-C | 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino [4, 5-b ] indole-1-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2008-03-26 | — | — | CN | disclosed |
| CN-1970538-A | Intermediate compounds of 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino [4, 5-b ] indole-1-acetamide derivatives | SANOFI AVENTIS (FR) | 2007-05-30 | — | — | CN | disclosed |
| EP-1458721-B1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO [4,5-B]INDOLE-1-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2006-11-22 | — | — | EP | disclosed |
| EP-1492792-B1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO¬4,5-B|INDOLE-1-ACETAMIDE DERIVATIVES, PREPARATION AND USE THEREOF IN MEDICAMENTS | SANOFI AVENTIS (FR) | 2006-03-29 | — | — | EP | disclosed |
| CN-1656099-A | 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino [4, 5-b ] indole-1-acetamide derivatives, their preparation and use in therapy | SANOFI AVENTIS (FR) | 2005-08-17 | — | — | CN | disclosed |
| CN-1604898-A | 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino [4, 5-b ] indole-1-carboxamide derivatives, preparation and therapeutic use thereof | SANOFI AVENTIS (FR) | 2005-04-06 | — | — | CN | disclosed |
| EP-1458721-A1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO 4,5-B]INDOLE-1-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | Sanofi-Aventis (FR) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003055884-A1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-B]INDOLE-1-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | SANOFI-SYNTHELABO (FR) | 2003-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039586-A1 | BICYCLIC COMPOUNDS AS ANDROGEN RECEPTOR MODULATORS | AR, FSHR, NR5A1 | HSD17B10 73/4885ALDH1A1 2558/4885KDM4E 1723/4885 |
| US-20150322052-A1 | ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1H | HSD17B10 3030/4885ALDH1A1 2882/4885KDM4E 830/4885 |
| US-20040077646-A1 | Indole nitriles | TPH1, IDO1, NAT1 | HSD17B10 2073/4885ALDH1A1 535/4885KDM4E 3071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.